药石科技: 关于提前赎回药石转债的第五次提示性公告

Core Viewpoint - Nanjing PharmaBlock Technology Co., Ltd. has announced the early redemption of its convertible bonds ("PharmaBlock Convertible Bonds") due to the triggering of conditional redemption clauses, aimed at reducing financial costs and optimizing capital structure [2][7]. Group 1: Convertible Bond Issuance and Redemption - The company issued 11.5 million convertible bonds at a face value of 100 RMB each, raising a total of 1.15 billion RMB on April 20, 2022 [2][3]. - The conditional redemption clause was triggered as the stock price exceeded 130% of the conversion price for at least 15 trading days [2][7]. - The redemption price is set at 100.62 RMB per bond, which includes accrued interest calculated based on a 1.5% annual interest rate [6][8]. Group 2: Redemption Process and Timeline - The redemption will take place on September 18, 2025, with trading of the bonds ceasing on September 15, 2025 [9]. - The company will notify bondholders daily leading up to the redemption date and will complete the redemption process by transferring funds to bondholders' accounts by September 25, 2025 [9]. - Following the redemption, the bonds will be delisted from the Shenzhen Stock Exchange [9]. Group 3: Conversion Price Adjustments - The conversion price of the bonds has been adjusted multiple times, with the latest adjustment setting it at 33.61 RMB per share as of May 30, 2025 [5][6]. - The conversion price adjustments are based on the company's stock performance and dividend distributions [4][5].